Name: South American Freight International, Inc. Address: 9000 W. Flagler Street, Unit

5, Miami, FL 33174. Date Revoked: May 7, 2011.

*Reason:* Failed to maintain a valid bond.

License Number: 14804N. Name: Metro Freight Int'l Inc. Address: 161–15 Rockaway Blvd.,

Suite 301, Jamaica, NY 11434. Date Revoked: May 1, 2011. Reason: Failed to maintain a valid

bond.

License Number: 018218N. Name: Pacheco Express Shipping Inc. Address: 1570 Webster Avenue,

Bronx, NY 10457. Date Revoked: May 8, 2011. Reason: Failed to maintain a valid bond.

*License Number:* 021442F. *Name:* Ferm Holdings, Inc. *Address:* 3460 NW 115th Avenue,

Miami, FL 33178.

Date Revoked: May 1, 2011. Reason: Failed to maintain a valid bond.

License Number: 022074F.

*Name:* Stream Links Express, Inc. dba E-Freight Solutions.

*Address:* 16328 Avalon Road, Gardena, CA 90248.

Date Revoked: May 6, 2011. Reason: Failed to maintain a valid bond.

#### Sandra L. Kusumoto,

Director, Bureau of Certification and Licensing. [FR Doc. 2011–13743 Filed 6–1–11; 8:45 am] BILLING CODE 6730–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

## Announcement of the Award of Nine Single-Source Expansion Supplement Grants

**AGENCY:** Office of Refugee Resettlement, ACF, HHS.

**ACTION:** Notice to announce the award of nine single-source expansion supplement grants to the Voluntary Agencies Matching Grant program grantees.

*CFDA Number:* 93.567. *Statutory Authority:* (A) Section 412 (c)(1)(A) of the Immigration and Nationality Act (INA)(8 U.S.C. 1522(c)(1)(A)), as amended, which authorizes the Director \* \* \*

\* \* \*to make grants to, and enter into contracts with, public or private nonprofit agencies for projects specifically designed-(i) to assist refugees in obtaining the skills that are necessary for economic selfsufficiency, including projects for job training, employment services, day care, professional refresher training, and other recertification services; (ii) to provide training in English where necessary (regardless of whether the refugees are employed or receiving cash or other assistance); and (iii) to provide where specific needs have been shown and recognized by the Director, health (including mental health) services, social services, education and other services.

(B) Refugee Assistance Extension Act of 1986, Public Law 99–605, Nov 6, 1986, 100 Stat. 3449:

# Section 7. Maintaining Funding Level of Matching Grant Program

(a) Maintaining Funding Level—Subject to the availability of appropriations, the Director of the Office of Refugee Resettlement shall not reduce the maximum average federal contribution level per refugee in the matching grant program and shall not increase the percentage grantee matching requirement under that program below the level, or above the percentage, in effect under the program for grants in fiscal year 1985.

(b) Matching Grant Program—The "matching grant program" referred to in subsection (a) is the voluntary agency program which is known as the matching grant program and is funded under section 412(c) of the Immigration and Nationality Act.

*Project Period:* February 1, 2011– September 30, 2011.

SUMMARY: The Office of Refugee Resettlement (ORR) announces the award of \$65,309,200 single-source expansion supplement grants to nine Voluntary Agencies Matching Grant Program cooperative agreement holders. The Voluntary Agencies Matching Grant Program currently operates on a program year from February 1 to January 31. ORR seeks to align the program with the Federal Fiscal Year. The singlesource expansion supplement grants will ensure that during the eight-month adjustment period, the ORR-eligible populations will continue to have access to program services without interruption.

Following is a listing of the awardees, their location, and their amount of award:

Grantee	Location	Amount of expansion supplement
Church World Service/Immigration & Refugee Program	New York, NY Arlington, VA	\$4,694,800 3,601,400 1,782,000 1,432,200 8,173,000 6,670,400 22,165,000 12,542,200 4,248,200

FOR FURTHER INFORMATION CONTACT: Mr. Eskinder Negash, Director, Office of Refugee Resettlement, Administration for Children and Families, 901 D Street, SW., Washington, DC 20047. Telephone: 202–401–5388. E-mail: Eskinder.Negash@acf.hhs.gov.

Dated: May 25, 2011.

## Eskinder Negash,

Director, Office of Refugee Resettlement. [FR Doc. 2011–13677 Filed 6–1–11; 8:45 am] BILLING CODE 4184–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

[Docket Nos. FDA-2011-M-0034, FDA-2011-M-0040, FDA-2011-M-0041, FDA-2011-M-0039, FDA-2011-M-0035, FDA-2011-M-0056, FDA-2011-M-0105, FDA-2011-M-0131, FDA-2011-M-0132, FDA-2011-M-0170, FDA-2011-M-0175, and FDA-2011-M-0198]

## Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications

**AGENCY:** Food and Drug Administration, HHS.

## ACTION: Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is publishing a list of premarket approval applications (PMAs) that have been approved. This list is intended to inform the public of the availability of safety and effectiveness summaries of approved PMAs through the Internet and the Agency's Division of Dockets Management.

**ADDRESSES:** Submit written requests for copies of summaries of safety and effectiveness data to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Please cite the appropriate docket number as listed in table 1 of this document when submitting a written request. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the summaries of safety and effectiveness.

## FOR FURTHER INFORMATION CONTACT:

Nicole Wolanski, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 1650, Silver Spring, MD 20993–0002, 301–796–6570.

## SUPPLEMENTARY INFORMATION:

## I. Background

In the **Federal Register** of January 30, 1998 (63 FR 4571), FDA published a final rule that amended 21 CFR 814.44(d) and 814.45(d) to discontinue individual publication of PMA approvals and denials in the **Federal Register**. Instead, the Agency now posts this information on the Internet on FDA's home page at http://www.fda.gov.

In accordance with section 515(d)(4)and (e)(2) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360e(d)(4) and (e)(2)), notification of an order approving, denying, or withdrawing approval of a PMA will continue to include a notice of opportunity to request review of the order under section 515(g) of the FD&C Act. The 30-day period for requesting reconsideration of an FDA action under §10.33(b) (21 CFR 10.33(b)) for notices announcing approval of a PMA begins on the day the notice is placed on the Internet. Section 10.33(b) provides that FDA may, for good cause, extend this 30-day period. Reconsideration of a denial or withdrawal of approval of a PMA may be sought only by the applicant; in these cases, the 30-day period will begin when the applicant is notified by FDA in writing of its decision.

The regulations provide that FDA publish a quarterly list of available safety and effectiveness summaries of PMA approvals and denials that were announced during that quarter. The following is a list of approved PMAs for which summaries of safety and effectiveness were placed on the Internet from January 1, 2011, through March 31, 2011. There were no denial actions during this period. The list provides the manufacturer's name, the product's generic name or the trade name, and the approval date.

TABLE 1—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM JANUARY 1,2011, THROUGH MARCH 31, 2011

		-	
PMA No. Docket No.	Applicant	Trade name	Approval date
P010012 (S230)	Boston Scientific Corp	BOSTON SCIENTIFIC CARDIAC RESYNCHRONI- ZATION THERAPY DEFIBRILLATORS.	September 16, 2010.
FDA-2011-M-0034			
P100021	Medtronic Vascular	MEDTRONIC VASCULAR ENDURANT STENT GRAFT SYSTEM.	December 16, 2010.
FDA-2011-M-0040			
P100010 FDA-2011-M-0041	Medtronic Cryocath, LP	ARCTIC FRONT CRYOCATHETER SYSTEM	December 17, 2010.
P070014 (S10)	Bard Peripheral Vascular	LIFESTENT AND LIFESTENT LX VASCULAR STENT SYSTEMS.	December 23, 2010.
FDA-2011-M-0039			
P070026 FDA-2011-M-0035	Depuy, Inc	CERAMAX CERAMIC HIP SYSTEM	December 23, 2010.
P100028	Cook Medical, Inc	FORMULA BALLOON-EXPANDABLE RENAL STENT SYSTEM.	January 14, 2011.
FDA–2011–M–0056			
P090013 FDA-2011-M-0105	Medtronic, Inc	REVO MRI SURESCAN IPG AND PACING SYSTEM	February 8, 2011.
P080003 FDA2011-M-0131	Hologic, Inc	SELENIA DIMENSIONS 3D SYSTEMS	February 11, 2011.
P080027 (S1) FDA-2011-M-0132	OraSure Technologies, Inc	ORAQUICK HCV RAPID ANTIBODY TEST	February 18, 2011.
H080005	Elana, Inc	ELANA SURGICAL KIT HUD	March 10, 2011.
FDA-2011-M-0170 P080025 FDA-2011-M-0175	Medtronic Neuromodulation	MEDTRONIC INTERSTIM THERAPY SYSTEM	March 14, 2011.